{"type":"img","src":"https://cdn.quv.kr/dftb6ow8k%2Fup%2F5c32ea85dae40_1920.png","height":90}
  • COMPANY
  • R&D PIPELINE
  • CRO SERVICES
  • CAREER
  • NEWS
  • CONTACT US
  • {"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Noto Sans KR","Nanum Barun Gothic"]}
    ×
    섹션 설정
    {"type":"img","src":"https://cdn.quv.kr/dftb6ow8k%2Fup%2F5c32ea85dae40_1920.png","height":50}
  • COMPANY
  • R&D PIPELINE
  • CRO SERVICES
  • CAREER
  • NEWS
  • CONTACT US
  • New Drug Candidate for Dry Eye syndrome

    RCI 001

    RCI001

     

     

    Candidate substance for dry eye treatment with strong anti-inflammatory action

     

    ▪ Patents for domestic use 10-1816277, U.S. patent application
       10-675294

    ▪ Domestic technology transfer: Hallym Pharmaceutical Co., Ltd.

    ▪ Overseas L/O goals after Phase 2 clinical trials

    ▪ 1st domestic clinical trial: 2022 3Q

    ▪ US FDA Phase 2: 2022 4Q

     

    {"google":["Noto Sans","Poppins"],"custom":["Noto Sans KR","Nanum Square","Nanum Barun Gothic","Jeju Gothic"]}{"google":["Noto Sans","Poppins"],"custom":["Nanum Square","Nanum Barun Gothic","Noto Sans KR","Jeju Gothic"]}
    {"google":[],"custom":["Noto Sans KR","Jeju Gothic"]}